Assertio Q2 Revenue Plunges 23% Amidst Product Sales Decline

Ticker: ASRT · Form: 10-Q · Filed: 2025-08-11T00:00:00.000Z

Sentiment: bearish

Topics: Pharmaceuticals, Earnings, Revenue Decline, Net Loss, 10-Q Filing, Biotech, Investor Warning

Related Tickers: ASRT

TL;DR

**Assertio's Q2 numbers are a red flag; revenue and profit drops signal deeper issues for this pharma stock.**

AI Summary

Assertio Holdings, Inc. reported a significant decline in revenue and net income for the second quarter and first half of 2025. Total revenue for Q2 2025 was $29.8 million, a sharp decrease from $38.9 million in Q2 2024, representing a 23.3% drop. Product revenue specifically fell to $29.8 million in Q2 2025 from $38.9 million in Q2 2024. For the six months ended June 30, 2025, total revenue was $60.2 million, down from $78.1 million in the same period of 2024, a 22.9% decrease. The company posted a net loss of $1.2 million in Q2 2025, a substantial decline from a net income of $1.5 million in Q2 2024. The diluted earnings per share also shifted from $0.02 in Q2 2024 to a loss of $0.01 in Q2 2025. This downturn is primarily attributed to decreased product sales, indicating challenges in their pharmaceutical portfolio. The strategic outlook remains focused on managing existing product lines amidst declining sales.

Why It Matters

Assertio's significant revenue and net income decline signals a challenging environment for investors, potentially impacting stock performance and future dividends. For employees, this could lead to cost-cutting measures or restructuring, creating job insecurity. Customers might see less investment in existing product lines or slower innovation if financial performance continues to deteriorate. In the broader pharmaceutical market, this decline highlights the intense competitive pressures and the need for a robust product pipeline to sustain growth, especially for smaller players like Assertio.

Risk Assessment

Risk Level: high — The company's risk level is high due to a 23.3% decrease in Q2 2025 revenue to $29.8 million from $38.9 million in Q2 2024, and a shift from a net income of $1.5 million to a net loss of $1.2 million in the same period. This significant financial deterioration indicates operational challenges and potential future instability.

Analyst Insight

Investors should consider reducing exposure to ASRT given the substantial revenue and net income declines. Await further clarity on strategic initiatives to reverse these trends before considering new positions.

Financial Highlights

revenue
$29.8M
net Income
-$1.2M
eps
-$0.01
revenue Growth
-23.3%

Revenue Breakdown

SegmentRevenueGrowth
Product Revenue$29.8M-23.3%
Royalty Revenue

Key Numbers

Key Players & Entities

FAQ

What were Assertio Holdings' total revenues for Q2 2025?

Assertio Holdings, Inc. reported total revenues of $29.8 million for the second quarter of 2025, a significant decrease from $38.9 million in Q2 2024.

Did Assertio Holdings, Inc. report a profit or loss in Q2 2025?

Assertio Holdings, Inc. reported a net loss of $1.2 million in Q2 2025, a downturn from a net income of $1.5 million in Q2 2024.

How did Assertio's diluted earnings per share change in Q2 2025?

Assertio's diluted earnings per share shifted from a positive $0.02 in Q2 2024 to a loss of $0.01 in Q2 2025, reflecting the company's declining profitability.

What was the revenue trend for Assertio Holdings in the first half of 2025?

For the six months ended June 30, 2025, Assertio Holdings' total revenue was $60.2 million, a 22.9% decrease from $78.1 million in the same period of 2024.

What are the primary reasons for Assertio Holdings' revenue decline?

The primary reason for Assertio Holdings' revenue decline is attributed to decreased product sales, indicating challenges within their existing pharmaceutical portfolio.

What is the risk level associated with Assertio Holdings based on this 10-Q?

Based on the 10-Q, the risk level for Assertio Holdings is high due to a 23.3% revenue drop and a shift from net income to net loss in Q2 2025.

What should investors consider regarding Assertio Holdings' stock?

Investors should consider reducing exposure to Assertio Holdings' stock given the substantial revenue and net income declines, and await clearer strategic plans for recovery.

When was Assertio Holdings' 10-Q filing for Q2 2025 submitted?

Assertio Holdings, Inc. filed its 10-Q for the period ended June 30, 2025, on August 11, 2025.

What is Assertio Holdings' business address?

Assertio Holdings' business address is 100 S. Saunders Road, Suite 300, Lake Forest, IL 60045.

How does Assertio's performance compare to the broader pharmaceutical market?

Assertio's significant decline in revenue and net income suggests it is underperforming compared to the broader pharmaceutical market, which generally requires strong product pipelines for sustained growth.

Risk Factors

Industry Context

Assertio Holdings operates in the pharmaceutical preparations industry, which is characterized by intense competition, patent expirations, and stringent regulatory oversight. Companies in this sector often rely on a portfolio of specialized drugs, with success dependent on effective marketing, R&D, and lifecycle management of existing products.

Regulatory Implications

As a pharmaceutical company, Assertio is subject to extensive regulation by bodies like the FDA. Changes in drug approval processes, pricing regulations, or compliance requirements can significantly impact revenue and profitability. The current financial downturn may also attract increased scrutiny regarding the company's operational and financial health.

What Investors Should Do

  1. [object Object]
  2. [object Object]
  3. [object Object]

Key Dates

Glossary

10-Q
A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document contains the financial data and disclosures for Assertio Holdings, Inc. for the specified quarter.)
Diluted EPS
Earnings per share (EPS) calculated by taking into account all dilutive securities, such as stock options and convertible bonds, which would reduce earnings on a per-share basis if exercised or converted. (Indicates the profitability on a per-share basis, reflecting the impact of potential share dilution. A decrease from $0.02 to -$0.01 highlights a significant deterioration in per-share profitability.)
Product Revenue
Revenue generated from the sale of the company's manufactured goods or products. (This is the primary source of revenue for Assertio, and its decline is the main driver of the overall revenue decrease.)

Year-Over-Year Comparison

Compared to the previous year's filings, Assertio Holdings has seen a substantial deterioration in its financial performance. Total revenue for Q2 2025 declined by 23.3% to $29.8 million from $38.9 million in Q2 2024, and the net income has swung from a profit of $1.5 million to a loss of $1.2 million. Diluted EPS also worsened from $0.02 to a loss of $0.01. No new significant risks were highlighted in the summary, but the existing risks related to declining sales and profitability have clearly materialized.

Filing Stats: 4,698 words · 19 min read · ~16 pages · Grade level 13.5 · Accepted 2025-08-11 16:10:58

Key Financial Figures

Filing Documents

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

Financial Statements (unaudited)

Item 1. Financial Statements (unaudited) Condensed Consolidated Balance Sheets at June 30, 2025 and December 31, 2024 Condensed Consolidated Statements of Comprehensive Loss for the three and six months ended June 30, 2025 and 2024 Condensed Consolidated Statements of Shareholders' Equity for the three and six months ended June 30, 2025 and 2024 Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024 Notes to Condensed Consolidated Financial Statements

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Controls and Procedures

Item 4. Controls and Procedures

— OTHER INFORMATION

PART II — OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings

Risk Factors

Item 1A. Risk Factors

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds Item 3. Defaults Upon Senior Securities Item 4. Mine Safety Disclosures Item 5. Other Information

Exhibits

Item 6. Exhibits

Signatures

Signatures 2

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS ASSERTIO HOLDINGS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share data) (Unaudited) June 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 47,086 $ 50,588 Short-term investments 51,097 49,466 Accounts receivable, net 61,090 54,120 Inventories, net 32,880 38,308 Prepaid and other current assets 18,056 10,067 Total current assets 210,209 202,549 Property and equipment, net 515 586 Intangible assets, net 62,006 80,471 Other long-term assets 1,050 1,126 Total assets $ 273,780 $ 284,732 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Accounts payable $ 10,854 $ 14,736 Accrued rebates, returns and discounts 85,887 76,304 Accrued liabilities 31,055 18,847 Contingent consideration, current portion 726 726 Other current liabilities 4,007 4,075 Total current liabilities 132,529 114,688 Long-term debt 39,046 38,813 Other long-term liabilities 8,907 10,150 Total liabilities 180,482 163,651 Commitments and contingencies (Note 9 ) Shareholders' equity: Common stock, $ 0.0001 par value, 200,000,000 shares authorized; 96,217,239 and 95,536,990 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively. 9 9 Additional paid-in capital 796,306 794,196 Accumulated deficit ( 703,017 ) ( 673,124 ) Total shareholders' equity 93,298 121,081 Total liabilities and shareholders' equity $ 273,780 $ 284,732 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 3 ASSERTIO HOLDINGS, INC. CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (in thousands, except per share data) (Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Revenues: Product sales, net $ 28,822 $ 30,695 $ 54,818 $ 62,557 Royalty revenue 400 431 894 1,017 Total revenues 29,222 31,126 55,712 63,574 Costs and expenses: Cost of sales 10,677 8,889 18,463 20,066 Re

View on Read The Filing